Public Health Archives - Page 2 of 35 - Boston Life Sciences Times

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

December 13, 2025

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

December 12, 2025

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

December 11, 2025

THIS WEEK'S STORIES

PepGen Names Joseph Vittiglio, Esq., Chief Business and Legal Officer

December 8, 2025

Aleta Biotherapeutics and Cancer Research UK Report Early Phase I/II Results for ALETA-001 in B-Cell Malignancies

December 9, 2025

Innoviva Specialty Therapeutics Reports Lancet Publication of Positive Phase 3 Data for Zoliflodacin in Gonorrhea

December 12, 2025

ABOUT US

Life Science Times is New England’s premier life sciences publication, covering the Pharma, Biotech, MedTech and Public Health sectors nationwide with a special focus on New England. Updated daily, we cover the latest news in everything else that touches any rubric of the rapidly growing life sciences industry.

Public Health

Federal Health Leaders Join Food Allergy Fund Forum to Chart Future of Research and Innovation

Dexcom Reveals Global Diabetes Advocates for World Diabetes Day

Brighton Marine Launches $100,000 Basic-Needs Initiative to Support Boston Veterans

New Research: GLP-1 Therapies Could Reduce U.S. Mortality by 3.5% Over the Next Two Decades

ByHeart Expands Voluntary Nationwide Recall of Infant Formula as Investigation Continues

Most Read

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

Acadia Pharmaceuticals Wins FDA Approval for DAYBUE STIX Powder Formulation for Rett Syndrome

ImmunityBio Wins EMA Recommendation for Conditional Approval of ANKTIVA With BCG for Bladder Cancer

Cosette Pharmaceuticals Terminates Agreement to Acquire Mayne Pharma

EDITOR PICKS

Capital Discipline Matters: Sam Zell’s Lessons for Every Entrepreneur

Kymera Therapeutics Closes Upsized $602 Million Public Offering, Underwriters Fully Exercise Option

Prilenia and Ferrer gain FDA approval to launch Phase 3 ALS study of pridopidine

THIS WEEK'S STORIES

PepGen Names Joseph Vittiglio, Esq., Chief Business and Legal Officer

Aleta Biotherapeutics and Cancer Research UK Report Early Phase I/II Results for ALETA-001 in B-Cell Malignancies

Innoviva Specialty Therapeutics Reports Lancet Publication of Positive Phase 3 Data for Zoliflodacin in Gonorrhea

POPULAR CATEGORY

ABOUT US

FOLLOW US